en POLSKI
eISSN: 2084-9834
ISSN: 0034-6233
Reumatologia/Rheumatology
Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
SCImago Journal & Country Rank


 
6/2021
vol. 59
 
Share:
Share:
more
 
 
abstract:
Original paper

The course of COVID-19 in patients with Behçet’s disease

Ayse Unal Enginar
1
,
Mustafa Gundogdu
2

1.
Department of Rheumatology, Konya City Hospital, Turkey
2.
Dermatology and Venereology Department, Ordu State Hospital, Turkey
Reumatologia 2021; 59, 6: 356–361
Online publish date: 2021/12/30
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Objectives
To evaluate the frequency and clinical course of coronavirus disease 2019 (COVID-19) in patients with Behçet’s disease (BD).

Material and methods
The study included patients diagnosed with BD according to the International Study Group for BD criteria who were being followed up in the Dermatology and Rheumatology clinics. Patients who applied to Rheumatology and Dermatology clinics and were not diagnosed with any rheumatological disease were taken as the control group. The medical records of the patients were examined retrospectively. A record was made of age, gender, additional systemic disease, for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), colchicine treatment dose, whether or not a polymerase chain reaction (PCR) test was performed, disease course in patients diagnosed with COVID-19, length of stay in hospital, and the need or not for intensive care unit (ICU) admission.

Results
Evaluation was made of 203 BD patients and a control group of 200 individuals. No difference was determined between the groups in respect of age and gender (respectively p = 0.348, p = 0.828). A polymerase chain reaction test for the SARS-CoV-2 was applied to 56 patients in the BD group, and 18 were reported positive, and to 80 subjects in the control group, of which 32 were determined positive. No difference was determined between the groups in terms of PCR test positivity (p = 0.321). No significant difference was determined between the groups in length of stay in hospital, lung involvement, ICU admissions, and mortality rates (respectively p = 0.684, p = 1.000, p = 0.503, p = 1.000). In the BD patient group, in all the parameters there was no significant difference between those who were positive or negative for COVID-19.

Conclusions
The results of this study showed no increased risk for BD patients compared to the normal population in respect of the frequency of SARS-CoV-2 infection, length of hospital stay, lung involvement, ICU admission and mortality.

keywords:

colchicine, Behçet’s disease, coronavirus disease (COVID-19), infection SARS-CoV-2







Quick links
© 2022 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.